Tranylcypromine NDC 70518-4708

NDC codes

FDA NDC Directory

Product NDC (as listed)70518-4708Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70518-4708Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70518-4708-0	70518470800	100 POUCH in 1 BOX (70518-4708-0) / 1 TABLET in 1 POUCH (70518-4708-1)Marketed from Jul 21, 2026

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Tranylcypromine
Generic name (nonproprietary): tranylcypromine
Active ingredients: Tranylcypromine sulfate — 10 mg/1
Dosage form: Tablet
Route: Oral
Labeler: REMEDYREPACK INC.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 213503
Marketing start: Jul 21, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Monoamine Oxidase Inhibitors (Mechanism)
Identifiers: Product ID 70518-4708_57321a72-7260-30d4-e063-6394a90a3fb3SPL ID 57321a72-7260-30d4-e063-6394a90a3fb3SPL set ID 83942f11-e10c-4c2d-ad78-880e1886064dRxCUI 313447UNII 7ZAT6ES870
Pharmacologic class: Monoamine Oxidase Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470518470800 followed by a unit qualifier and the quantity

Package 70518-4708-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 22, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Tranylcypromine tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. Tranylcypromine tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see Contraindications (4) , Warnings and Precautions (5) , and Drug Interactions (7) ] . Tranylcypromine tablets are a monoamine oxidase inhibitor (MAOI) indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants ( 1 ) Tranylcypromine tablets are not indicated f…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 213503

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 213503
Product	Strength	Form · route	Labeler	Product NDC
Tranylcypromine	Tranylcypromine sulfate 10 mg/1	TabletOral	Solco Healthcare US, LLC	43547-655